Clinical Trial Update: Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant trial of Sunvozertinib for potentially resectable EGFR exon 20 insertion non-small cell lung cancer (Stage II–IIIB); the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING